Skip to content
Disclosery

Pivotal bioVenture Partners Investment Advisor LLC

Follow

13F filer, CIK 1844645, SAN FRANCISCO, CA

Pivotal bioVenture Partners Investment Advisor LLC reported $161,342,907 across 12 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-13. Its ten largest share positions make up 99.16% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-25-000438

Period
2025-06-30
Reported value
$161M
Holdings
12
Top 10 weight
99.16%
New
2
Sold out
1

Part of the filer group Pivotal bioVenture Partners Investment Advisor LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PCVXadded+594,391$19.3M
TRVInew+1,146,110$6.27M
BOLTnew+94,573$546K
ZBIOadded+42,400$411K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BOLT BIOTHERAPEUTICS INCexited-1,891,467-$757K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001012975-25-000438, largest first. % of portfolio is the value over $161,342,907, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,595,918 shares; 2024Q4: 1,737,696 shares; 2025Q1: 2,300,774 shares; 2025Q2: 2,300,774 shares 2,300,774$44.7M27.68%0Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 639,539 shares; 2024Q4: 703,834 shares; 2025Q1: 710,734 shares; 2025Q2: 1,305,125 shares 1,305,125$42.4M26.3%+594,391Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,120,508 shares; 2024Q4: 2,120,508 shares; 2025Q1: 2,120,508 shares; 2025Q2: 2,120,508 shares 2,120,508$29.7M18.43%0Timeline
INOZYME PHARMA INCINOZYME PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,494,851 shares; 2024Q4: 4,494,851 shares; 2025Q1: 4,494,851 shares; 2025Q2: 4,494,851 shares 4,494,851$18M11.14%0
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 650,695 shares; 2024Q4: 736,645 shares; 2025Q1: 736,645 shares; 2025Q2: 779,045 shares 779,045$7.55M4.68%+42,400Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,146,110 shares 1,146,110$6.27M3.89%newTimeline
VIGIL NEUROSCIENCE INCVIGIL NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 560,595 shares; 2024Q4: 560,595 shares; 2025Q1: 560,595 shares; 2025Q2: 560,595 shares 560,595$4.46M2.76%0
RXRXRECURSION PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 595,518 shares; 2025Q1: 595,518 shares; 2025Q2: 595,518 shares 595,518$3.01M1.87%0Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 527,647 shares; 2024Q4: 653,374 shares; 2025Q1: 653,374 shares; 2025Q2: 653,374 shares 653,374$2.7M1.67%0Timeline
IOBTQIO BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 864,197 shares; 2024Q4: 864,197 shares; 2025Q1: 864,197 shares; 2025Q2: 864,197 shares 864,197$1.2M0.74%0Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,404,644 shares; 2024Q4: 2,404,644 shares; 2025Q1: 2,404,644 shares; 2025Q2: 2,404,644 shares 2,404,644$813K0.5%0
BOLTBOLT BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 94,573 shares 94,573$546K0.34%newTimeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BOLT BIOTHERAPEUTICS INCBOLT BIOTHERAPEUTICS INC1,891,467$757Kshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-25-000438 base2025-08-13acceptance time not in the bulk data set